MDS/MPN overlap syndromes have long been difficult to define and diagnose since they were discovered. They have similar features, symptoms and test results to other myeloid neoplasms like MDS and MPN which makes it hard to diagnose. By using next generation sequencing, hematologists/oncologists are able to better understand these syndromes and plan a course of treatment that is more effective and has better outcomes.
Dr. Hunter will review changes in understanding clinicians and researchers have about diagnosing and treating these overlapping syndromes (including chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia, MDS/MPN with ring sideroblasts and thrombocytosis and MDS/MPN unclassifiable).